Caris Life Sciences is a private precision-medicine and molecular diagnostics company focused on cancer care. It uses genomic, transcriptomic, proteomic, and AI-driven analysis to help physicians match patients to more personalized treatment options.
Access to pre-IPO shares is available to accredited investors through UpMarket.
Caris Life Sciences shares are not on public exchanges. UpMarket provides accredited investors access through secondary market transactions.
Confirm eligibility under SEC Rule 501 of Regulation D. Income or net worth threshold applies.
Complete KYC/AML onboarding. Typically 1–2 business days. Licensed rep assigned on signup.
Full offering memoranda and risk disclosures provided before any commitment is required.
Review and sign subscription agreement. All documents handled digitally through the platform.
Wire transfer or ACH. $50K minimum. Funds held in custodial account until close.
Pre-IPO investments are illiquid, speculative, and involve risk of total loss of capital.
| Date | Round | PPS (split-adj.) | Valuation |
|---|---|---|---|
| 2025 | IPO |
Caris Life Sciences announced an $830 million growth equity round at a $7.83 billion post-money valuation in May 2021. The company said the financing brought total external funding since 2018 to about $1.3 billion and backed commercial expansion.
In its 2020 growth-capital announcement, Caris said it used AI on a 215,000-patient database with molecular and clinical outcome data. The company described its tumor profiling platform as market-leading, with broad actionable biomarker coverage and proprietary molecular signature analytics.
Caris said new capital would support a first-in-class liquid biopsy platform for therapy selection, recurrence monitoring, and early screening across cancer types. The company also said it would expand clinical trial delivery services and biopharmaceutical partnerships, widening its precision-medicine market.
Interested in Caris Life Sciences stock? Fill out the form above or sign up directly. Subject to availability. Accredited investors only.
Request access →UpMarket curates and conducts independent diligence on every investment opportunity before it reaches the platform.
We review every offering's strategy, risk management, liquidity, fees, valuation methodology, tax matters, and all third-party providers — legal counsel, auditor, administrator, and custodian.
We offer investments exclusively from disciplined managers that pursue unique strategies across an array of asset classes.
Our goal is to empower you to build a portfolio that best meets your individual investment objectives.
No. As of March 2026, Caris Life Sciences is a private company and does not trade on any public stock exchange. Accredited investors can access Caris Life Sciences shares through UpMarket, a FINRA-registered broker-dealer that specializes in pre-IPO investments.
Caris Life Sciences does not have a public stock price because it is privately held. The most recent known share price comes from its last funding round. Pre-IPO share prices on the secondary market may differ from the last round price depending on supply, demand, and market conditions.
Yes. Accredited investors can indicate interest in Caris Life Sciences shares through UpMarket by filling out the form on this page or creating an account at upmarket.co. All pre-IPO offerings are subject to availability and require a $50,000 minimum investment. UpMarket is a FINRA-registered broker-dealer and has brokered more than $500M in alternative investments since 2019.
Pre-IPO investments carry significant risks. Caris Life Sciences shares are illiquid, meaning there is no public market to sell them quickly. There is no guaranteed exit timeline or return. The investment is speculative in nature, and investors should be prepared for the possibility of total loss. Valuations of private companies can fluctuate substantially between funding rounds. Investors should consult their financial advisor and review all offering documents before investing.
In a pre-IPO transaction, accredited investors purchase shares from existing shareholders (such as employees, early investors, or other holders) through secondary market platforms. The company itself does not issue new shares in these transactions. UpMarket facilitates these trades as a FINRA-registered broker-dealer, handling compliance, documentation, and settlement on behalf of both parties.
There are two primary exit paths for pre-IPO holdings: selling your shares on the secondary market to another buyer, or holding until the company completes an IPO or is acquired. Both paths are subject to transfer restrictions, company approval (right of first refusal), and market conditions. The timing of any exit is unpredictable, and investors should plan for a multi-year holding period.
The minimum investment for most pre-IPO offerings on UpMarket is $50,000. This amount may vary depending on the specific offering and share availability. There are no fees to create an UpMarket account or browse available investments. Investors only pay transaction-related fees when they complete an investment.
UpMarket's valuation estimate of is derived from a proprietary model that incorporates multiple data sources: funding round data (Caplight), revenue estimates (Sacra), secondary market pricing, and public company comparables. The model applies a private company discount to the public comp multiple to account for illiquidity and information asymmetry. This estimate is not investment advice and may differ substantially from the price at which shares actually trade.
Caris Life Sciences generated $812.0M in 2025 revenue and uses genomic, transcriptomic, proteomic, and AI-driven analysis for cancer care, after raising $830M at a $7.83B valuation in 2021 — accredited investors can access Caris Life Sciences stock through UpMarket.